Nasdaq Correction: 3 Things Every Investor Should Know
The Nasdaq, along with the S&P 500 and the Dow Jones Industrial Average, roared higher over the past two years, delivering double-digit annual gains. And the momentum continued into this year as investors piled into high-growth companies involved in hot technologies such as artificial intelligence and quantum computing -- until recently.
Over the past few weeks, a drop in consumer confidence in February and a weaker-than-expected jobs report fueled uncertainty about the economy and the potential effect on corporate earnings. And investors also worried about the impact of certain moves from President Trump -- for example, the launch of tariffs on imports from Mexico, Canada, and China. Trump introduced the tariffs early last week, though he delayed them by one month on items covered by the United States-Mexico-Canada Agreement.
As a result, some of the strongest growth stocks, from Nvidia (NASDAQ: NVDA) to Amazon, have seen their shares tumble and last week dragged the tech-heavy Nasdaq into correction territory. This downturn may make you wonder whether you really should be buying stocks right now. Before deciding, though, here are three things every investor should know about the Nasdaq correction.
The Nasdaq entered a correction on March 6, falling more than 10% from a peak on Dec. 16, though it showed signs of recovery during the next trading session, ending the week down by 9.8% from that point. (For an index to be considered in correction territory, it must fall by 10% to 20% from its most recent high.)
It's too early to say whether this correction period will last, but here's a positive point to keep in mind: History shows us that corrections generally have led to positive performance. Of 11 Nasdaq corrections since 2010, 10 have resulted in positive performance in the 12 months to follow, and the average annual gain has been more than 21%. Of course, history doesn't always repeat itself, but at least this trend shows us corrections don't necessarily mean a bigger drop is just ahead.
No investors like seeing stocks in their portfolio tumble. But there is one positive point about a market correction, and that's the opportunity to add to some of your favorite positions, potentially for a bargain -- and find new buying opportunities, too.
Though we all loved seeing stocks soar in recent times, the downside was that valuations of many players took off, too. We can use prices of S&P 500 stocks as an example, and one of the best ways to do this is by looking at the Shiller CAPE ratio. This metric considers stock prices and earnings per share over a 10-year period to adjust for fluctuations in the economy.
As the bull market roared higher, this measure reached the level of 37, something it's done only twice before since the launch of the benchmark as a 500-company index in the late 1950s. Though it still is high at the level of 35 today, it has started to come down.
And this happens as many stocks, including Nasdaq players such as Nvidia and Amazon, drift into bargain territory as part of the current market declines. Nvidia now trades for 25 times forward earnings estimates, down from 48 earlier this year. And Amazon now trades for 31 times forward estimates, compared with 45 just a few months ago. So now looks like a great time to go bargain hunting.
OK, so I know it's hard to just ignore what's going on at the moment, especially if your portfolio is suffering. But at times like this, it's important to shift your focus from today to the long term. If you look at stock performance from this perspective, you'll notice that indexes always have recovered after tough periods and gone on to advance, as we can see in this chart of the Nasdaq's performance since 2010 -- the time of the first correction I mentioned earlier.
In fact, each correction looks small from this lens, suggesting that if you invest in quality companies or related assets such as exchange-traded funds, these tough times probably won't affect your returns by much at all. By long term, I mean holding on for at least five years, but even better if the stocks you select make great holdings for 10 years or longer.
That's why it's crucial to go for companies with solid long-term prospects that won't be significantly hurt during times of economic headwinds and tough markets. If you do this, you'll sleep a lot easier during market corrections, feel better about scooping up those bargains I talked about, and potentially set yourself up for a long-term win.
Ever feel like you missed the boat in buying the most successful stocks? Then you'll want to hear this.
On rare occasions, our expert team of analysts issues a 'Double Down' stock recommendation for companies that they think are about to pop. If you're worried you've already missed your chance to invest, now is the best time to buy before it's too late. And the numbers speak for themselves:
Nvidia: if you invested $1,000 when we doubled down in 2009, you'd have $292,207!*
Apple: if you invested $1,000 when we doubled down in 2008, you'd have $45,326!*
Netflix: if you invested $1,000 when we doubled down in 2004, you'd have $480,568!*
Right now, we're issuing 'Double Down' alerts for three incredible companies, and there may not be another chance like this anytime soon.*Stock Advisor returns as of March 3, 2025
John Mackey, former CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. Adria Cimino has positions in Amazon. The Motley Fool has positions in and recommends Amazon and Nvidia. The Motley Fool has a disclosure policy.
Nasdaq Correction: 3 Things Every Investor Should Know was originally published by The Motley Fool
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
36 minutes ago
- Yahoo
UnitedHealth Group (NYSE:UNH) Announces Debt Financing Totalling US$3 Billion
UnitedHealth Group recently completed a substantial debt financing deal, raising $3 billion through the issuance of various Notes. This move comes amid a period of legal settlements, such as the $69 million ERISA case, and operational restructuring, including exploring bids for its Latin American operations. Despite these significant developments, the company's stock price remained relatively flat over the last month, reflecting broader market trends which also showed minimal movement. The dividend increase and shareholder discussions on executive compensation may have subtly influenced sentiment, but overall, these events seemed to align with the market's flat performance. UnitedHealth Group has 1 possible red flag we think you should know about. Trump has pledged to "unleash" American oil and gas and these 22 US stocks have developments that are poised to benefit. UnitedHealth Group's recent $3 billion debt financing and restructuring efforts, such as evaluating bids for its Latin American operations, are significant developments. While the near-term stock price remained relatively stable amid these changes, over the past five years, the company's total shareholder return, including dividends, was 13.61%. This reflects a steady growth trajectory, although in the last year, UnitedHealth underperformed the US Healthcare industry. The current share price sees a slight discount from the analyst consensus price target of $547.65, which is 28% higher than the present value. Despite recent legal settlements and compensation discussions, the company's aggressive push towards digital tools and Medicare adjustments might bolster future earnings and revenue. UnitedHealth's projected earnings per share and revenue growth is positioned slightly behind broader market expectations over the next few years, yet planned improvements in operational efficiencies could bridge this gap over time. Learn about UnitedHealth Group's future growth trajectory here. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NYSE:UNH. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
36 minutes ago
- Yahoo
Teradyne (NasdaqGS:TER) Revamps By-Laws to Modernize Shareholder Procedures and Director Elections
On June 20, 2025, Teradyne implemented significant amendments to its By-Laws, adjusting nomination and proposal notice windows and clarifying voting standards. Over the past month, Teradyne's stock price moved 9% amid these changes, potentially reflecting investor confidence in enhanced governance practices. Although the broader market has remained flat, the recent gains by the company could suggest that these internal updates resonated positively with market participants, aligning with an overall upward market trend over the past year. This internal shift may have added weight to Teradyne's modest divergence from the market's flat performance. Buy, Hold or Sell Teradyne? View our complete analysis and fair value estimate and you decide. These 17 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch. The recent amendments to Teradyne's by-laws could potentially reinforce investor confidence, aligning with broader market interests in strong governance. Over a longer five-year span, Teradyne's total shareholder return of 7.61% provides context for its performance, despite the stock's short-term fluctuations. This return contrasts with the company's one-year underperformance, as it lagged behind both the overall US market and the semiconductor industry, indicating room for improvement. The governance changes could influence Teradyne's revenue and earnings positively, particularly in the context of its strategic focus on AI, robotics, and automation. These areas are anticipated to boost revenue, though current geopolitical and tariff concerns could pose risks. Analysts forecast an annual revenue growth of 12.3% and a rise in profit margins to 24.7%, indicating a potential upside, even if challenges persist. The recent share price movement following the changes, while reflective of immediate investor sentiment, shows a notable gap against the consensus price target of US$99.83, which represents a 25.8% potential increase from the current US$74.07. This suggests that investors might be weighing the company's long-term strategic initiatives against current uncertainties. Our valuation report unveils the possibility Teradyne's shares may be trading at a discount. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NasdaqGS:TER. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Are These 2 'Strong Buy' Rated Growth Stocks Buys Right Now?
Investing in biotech penny stocks is fraught with volatility, regulatory hurdles, and uncertain clinical results. Penny stocks are companies that trade for less than $5 per share. However, for those with a high risk tolerance, these small-cap stocks can provide outsized returns, particularly when scientific breakthroughs or U.S. Food and Drug Administration (FDA) approvals result in explosive gains. With Wall Street analysts issuing 'Strong Buy' ratings on these two high-potential plays, let's dig in to see whether these growth stocks could deliver on their promises. With a market capitalization of $21 million, Ovid Therapeutics is a small clinical-stage biopharmaceutical company focused on developing treatments for rare neurological disorders. Ovid's business model is centered on central nervous system (CNS) disorders, which are a challenging therapeutic area. Its pipeline includes novel compounds in early- to mid-stage development that target epilepsy and other genetically based neurological disorders. OVID stock has fallen 67.6% year-to-date (YTD), compared to the S&P 500 Index's ($SPX) gain of 1.6%. Dear Tesla Stock Fans, Mark Your Calendars for June 30 3 ETFs with Dividend Yields of 12% or Higher for Your Income Portfolio This Options Tool Can Show You How to Trade Tesla Stock Ahead of Robotaxi Day Get exclusive insights with the FREE Barchart Brief newsletter. Subscribe now for quick, incisive midday market analysis you won't find anywhere else. Ovid currently has no FDA-approved products on the market. However, Wall Street analysts have called OVID a "Strong Buy," with all six analysts covering the stock rating it as such. Still, the company has also received a delisting notice from Nasdaq for failing to maintain the minimum bid price of $1.00 per share. Ovid has until Aug. 11, 2025, to regain compliance by maintaining a closing bid price of at least $1.00 for 10 consecutive trading days. Ovid's pipeline is small in size but very targeted. The most closely watched candidate is OV329, a highly selective small-molecule inhibitor of GABA aminotransferase (GABA-AT). OV329 is intended to treat epilepsy that has not responded to previous treatments. In preclinical models, the candidate has shown promise in controlling seizures while causing fewer side effects than existing treatments such as vigabatrin. Ovid Therapeutics anticipates Phase 1 trial results in the third quarter of 2025. The company has a good chance of its stock ticking upwards if the Phase 1 topline results for OV329 turn out positive. Ovid's other candidate is OV350, a next-generation KCC2 modulator that is also being tested in a Phase 1 trial. The company generated $130,000 in revenue from royalty agreements during Q1. At the end of the quarter, its cash, equivalents, and marketable securities totaled $43 million. This gives the company an estimated runway through the second half of 2026. Ovid has received a 'Strong Buy' rating on Wall Street because of its rich pipeline of rare disease treatments. The stock may appeal to long-term aggressive investors who are comfortable with volatility and have a strong interest in innovative science. However, I believe investors should wait until Ovid either clears the $1 delisting threshold or proves its clinical strategy with positive results. Analysts have an average target price of $2.88 for the stock, which implies upside potential of 860% from current levels. The Street-high price estimate stands at $4 for OVID stock. With a market cap of $609 million, Nuvation Bio is a clinical-stage biotech company that develops targeted oncology treatments for challenging cancers with limited treatment options. However, it may soon release a revenue-generating product to the market this year. NUVB stock is down 27.7% YTD, compared to the overall market gain. Nuvation Bio's pipeline includes programs addressing a variety of oncology targets, including breast, ovarian, and lung cancer. Its pipeline currently consists of four core programs: taletrectinib (ROS1 inhibitor), NUV-1511 (drug-drug conjugate), safusidenib (brain-penetrant IDH1 inhibitor), and NUV-868 (BET inhibitor). Taletrectinib, Nuvation's lead candidate for the treatment of ROS1+ and advanced non-small cell lung cancer, has already been approved in China and the United States. The company hopes to begin commercializing taletrectinib in mid-2025. In March, the firm secured $250 million in non-dilutive financing from Sagard Healthcare Partners, as well as $150 million in royalty financing and $50 million in debt, subject to approval. Nuvation also has the option to secure an additional $50 million in debt until June 30, 2026 if it completes its first commercial sale in the United States. Safusidenib is currently in Phase 2 trials, and NUV-1511 is in Phase ½ trials. The company intends to provide updates for both during the second half of 2025. Nuvation ended Q1 with $461.7 million in cash, cash equivalents, and marketable securities. A favorable FDA decision could open up significant market opportunities for the company. Nuvation Bio's late-stage pipeline, strong cash position, and clear commercialization path make it an appealing biotech growth stock to buy right now. However, the company's ability to generate profits after commercialization may take years, making it an appropriate choice for those with a high risk tolerance and a longer investment horizon. Overall, Wall Street rates NUVB stock a 'Strong Buy.' Of the seven analysts covering the stock, six rate Nuvation as a 'Strong Buy' while one recommends a 'Moderate Buy" rating. The average price target of $7.17 suggests that NUVB stock could rally around 258% over the next 12 months. The high price estimate of $10 suggests a gain of 400% over current levels. On the date of publication, Sushree Mohanty did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on
